• News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Rights Issue / Företrädesemission 2022
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Contact
logo
  • News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Rights Issue / Företrädesemission 2022
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Contact
Home / Investors / The Share
  • Overview
  • Rights Issue / Företrädesemission 2022
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • Company Presentation
  • The Share
    • Share Monitor
    • Largest Shareholders
    • Share Capital Development
    • Rights Issues / Företrädesemissioner
    • Analyst Coverage
  • Financial Reports
    • English
    • Swedish
  • Financial Calendar
  • Corporate Governance
    • General Meetings
    • Nomination Committee / Valberedning
    • Previous Nomination Committees
    • Auditor
    • Articles of Association
    • Board of Directors
    • Management
  • Certified Adviser
  • IR Contact

Share Monitor

The Alzinova share is traded on Nasdaq First North Growth Market. The company has a registered share capital of 8,526,205.942 SEK, divided on 32,419,034 shares. The quota value is 0.263 SEK/share.

Name: Alzinova AB
Ticker: ALZ
ISIN code: SE0007413455
LEI-code: 549300K3IMVT20EK2S13

Shares are registered by Euroclear Sweden AB

  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin